Upload
invest-northern-ireland
View
118
Download
2
Tags:
Embed Size (px)
Citation preview
Horizon 2020: SME Instrument Case Study
Dr Lorraine Martin
Chief Executive Officer
Co-founder
Fast Track to Innovation Seminar – 20 Jan 2015
Background
Technology & Innovation
Roadmap to commercialisation
Horizon 2020 – SME Instrument
Primary considerations
Proposal preparation & submission
Award & grant agreement preparation
Tangible Benefits
ProAxsis: On the fast track
Fast Track to Innovation Seminar – 20 Jan 2015
Technology: Identification of an active problem
CancerHeart
DiseaseInfection
Respiratory Disease
Diagnostic and prognostic value:Drug targets and Biomarkers of disease activity
Active proteases are of biomedical and
pharmaceutical importance e.g.
No tools available in the clinic or home to
monitor predictive spikes of protease activity
Fast Track to Innovation Seminar – 20 Jan 2015
Innovative solutions to an active problem
Protease-Tag
PROTEASE
PROTEASE
PROTEASE
PROTEASE
ProteaseTagsTM
Inactivate a specific protease
and may be used as tools to
detect and quantify the
activity of a single protease
species within a complex
biological sample
Protease-TagTM Technology:
Novel and rapid method of
detecting active protease
biomarkers
• Potential to be
incorporated into a
number of technology
platforms
• Multi-analyte
• Product pipeline
Roadmap to commercialisation
Proof of Concept Awards; £100K x2
Confidence in Concept
£100K
Commercial Development Award
£118K
2008
2012
2013
2009
Spin-out
Fast Track to Innovation Seminar – 20 Jan 2015
SMART MOLECULES
ProteaseTagsTM
“DESIGN & SYNTHESIS”
CLINICAL RESEARCH
SERVICES
ACTIVITY PROFILING
TARGET VALIDATION
CLINICAL TRIAL SUPPORT
CLINICAL/
POINT OF CARE TESTS
DEVELOPMENT OF LATERAL
FLOW DEVICES WITH
ASSOCIATED HAND-HELD
READER TECHNOLOGY
ProteaseTagTM ELISAs
KIT SALES
SERVICE PROVISION
DRUG DISCOVERY
LICENCING OPPORTUNITIES
Active markets requiring smart solutions
Constitute global sales of $7.2 billion.
Expected to double by 2020.
Rapidly growing market predicted to
be worth £20.9 billion by 2015
Horizon 2020 – Identify a call
Call ID PHC 12 -2014/15: Clinical validation of
biomarkers and/or diagnostic medical devices
Developing a test for use at point of care for a chronic
disease of significant burden across Europe and globally
Phase 1: ENABLE: Establishment of a Neutrophil elastase
Activity home test for the Better management and treatment of
Lung Exacerbations
Phase 2: MONITOR: Measurement Of Neutrophil elastase In the
management and Treatment Of chronic Respiratory disease
Evaluate preparation time/effort vs tangible benefits
Direct benefits:
Phase 1: €50K (70% funding), lump sum for “deliverable” to
progress a work package
Indirect benefits:
PR, exposure, heightened profile
“Deliverable” pump primes Phase 2 application: £M
(100% funding)
Get some feedback Invest NI
Primary considerations
H2020
Advisors
Fast Track to Innovation Seminar – 20 Jan 2015
Fast Track to Innovation Seminar – 20 Jan 2015
Start the process – Registration
Never too early to register with the Participants Portal
Personal info, company info, financials
******** ********
Fast Track to Innovation Seminar – 20 Jan 2015
However, some things can be left . . .
E.g. LEAR validation
If in doubt - ask
Acquire PIC number******
*
Start the process – PIC Number
Fast Track to Innovation Seminar – 20 Jan 2015
Proposal preparation
Follow the instructions!
Proposal submission document (electronic)
Proposal in 2 parts – sections 1-3 & 4-5 (separate documents)
Read the questions and address each point
Be careful with jargon and clearly note abbreviations
Consider impact - think outside the box
European application – use Euro’s for markets and
compile as much cross-Europe data as possible
Think carefully about task list – follow guidance
Get feedback
Receipt of Award -Evaluation Summary Report
Fast Track to Innovation Seminar – 20 Jan 2015
Total score (out of 15.00; threshold 13.00)
Criterion 1
Impact (threshold 4.00/5.00)
Criterion 2
Excellence (threshold 4.00/5.00)
Criterion 3
Quality & efficiency of implementation (threshold 4.00/5.00)
Final assessment:
Proposal content corresponds, wholly or in part to the topic
description against which it is submitted, in the relevant work
programme part?
Status – YES/NO
All validations need to be completed
Financial identification form
Legal entity
Confirmation of private company, VAT, current
appointments etc
LEAR (Legal entity appointed representative)
Declaration of honour
Part B: merging of sections 1-3 and 4-5 to a
single document exc task list (inputted
separately)
Grant Agreement preparation stage
Fast Track to Innovation Seminar – 20 Jan 2015
Summary of Process
CALL ID
Registration
Proposal Preparation
Submission
Grant Agreement
Preparation
Validations
Signing off
Transfer of % funds
Receipt of award letter
Fast Track to Innovation Seminar – 20 Jan 2015
Tangible benefits & PR
Horizon 2020 SME Instrument
€50K lump sum to support the building of resources for the
preparation of Phase 2; no detailed financial accounting
Familiarity with the portal and process, prior to submission of
larger phase 2
PR and company exposure
Press releases
Fast Track to Innovation Seminar – 20 Jan 2015
• British Influence @britinfluence Sep 18 @ProAxsis Congratulations
on securing an EU SME Instrument grant!
http://bit.ly/1o5aEiM http://bit.ly/UuYHtQ
• Stratified Medicine retweeted a Tweet you were mentioned in
Sep 22: @EU_Commission announce @ProAxsis secured an EU
SME Instrument #grant! Sending our congrats!
http://bit.ly/1o5aEiM http://bit.ly/UuYHtQ
• Sep 23: Congratulations to Dr Lorraine Martin @QUBPharmacy on
being among the first to receive a EU SME Instrument grant.
• H2020 SME Instrument @H2020SME Oct 16 #H2020
#SMEinstrument project: ENABLE Neutrophil elastase activity home
test for better treatment of lung exacerbations by @ProAxsis, UK
• MRC Impact @MRCeVal Nov 14 New @MRCcomms spin outs inc
@ProAxsis from @QueensUBelfast voted one of NI promising tech
companies http://bit.ly/1xWRZLI #researchfish
• H2020 SME Instrument @H2020SME Dec 4 #H2020
#SMEinstrument project: ENABLE Neutrophil elastase activity home
test for better treatment of lung exacerbations by @ProAxsis UK
Tangible benefits & PR
Horizon 2020 SME Instrument
€50K lump sum to support the building of resources for the
preparation of Phase 2; no detailed financial accounting
Familiarity with the portal and process, prior to submission of
larger phase 2
PR and company exposure
Press releases
Linkedin contacts
Potential opportunities for collaboration
Fast Track to Innovation Seminar – 20 Jan 2015
On the Horizon
Horizon 2020 SME Instrument
Completion of Phase 1 deliverable
Clinical validation & regulatory
approval of PoC test
Phase 2 preparation & submission
Fast Track to Innovation Seminar – 20 Jan 2015
CONTACT
Dr Lorraine Martin
ProAxsis Ltd
63 University Road
Belfast BT7 1NF
Phone: +44 (0)2890 975711
Email: [email protected]
www.proaxsis.com
Follow on Twitter @proaxsis